Isolation of Mycoplasma genitalium from clinical specimens remains difficult and few strains\nare available for antimicrobial susceptibility testing. We describe the antimicrobial susceptibility\nof M. genitalium strains grown in Vero cell culture with first- and second- line antibiotics,\nusing a modified cell-culture-based method. Macrolide- and -fluoroquinolone\nresistance determinants were detected by sequencing of the 23S and parC genes, respectively.\nSeven strains were examined, including three new, genetically distinct M. genitalium\nstrains isolated from endocervical and urethral swab specimens from Cuban patients\ntogether with four reference strains isolated from specimens collected from men in Denmark,\nSweden and Australia. Azithromycin was the most active drug against two of the\nCuban M. genitalium strains with MICs values of 0.008 mg/liter, however, one strain was\nmacrolide resistant with an MIC of 8 mg/liter, and the A2059G resistant genotype. Ciprofloxacin\nwas the least active antimicrobial drug and moxifloxacin was the most active fluoroquinolone\nagainst the new clinical strains, although an MIC of 1 mg/l was found for two\nstrains. However, no relevant parC mutations were detected. MICs for tetracyclines were\n0.5ââ?¬â??4 mg/liter. Although the number of Cuban strains was low, the results suggest that a\nsingle-dose azithromycin treatment could be ineffective, and that a second-line treatment\nwith moxifloxacin, should become an option in Cuba. To our knowledge, this is the first\nreport of isolation and antibiotic susceptibility testing of M. genitalium strains from the Latin-\nAmerican region, and the first detection of macrolide resistance in such strains.
Loading....